Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
- PMID: 18669461
- DOI: 10.1200/JCO.2007.15.5416
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Abstract
Purpose: To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response.
Patients and methods: Patients with mRCC and disease progression after bevacizumab-based therapy received oral sunitinib 50 mg once daily in 6-week cycles on a 4/2 schedule (4 weeks with treatment followed by 2 weeks without treatment) in a phase II multicenter study. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), duration of response (DR), overall survival (OS), and safety. Plasma soluble proteins (vascular endothelial growth factor [VEGF]-A, VEGF-C, soluble VEGF receptor [sVEGFR]-3, and placental growth factor [PlGF]) levels were measured.
Results: Sixty-one patients were enrolled. The ORR was 23.0% (95% CI, 13.2% to 35.5%), median PFS was 30.4 weeks (95% CI, 18.3 to 36.7 weeks), median DR was 44.1 weeks (95% CI, 25.0 to 102.7 weeks), and median OS was 47.1 weeks (95% CI, 36.9 to 79.4 weeks). Mean plasma VEGF-A and PlGF levels significantly increased whereas VEGF-C and sVEGFR-3 levels decreased with sunitinib treatment. Lower baseline levels of sVEGFR-3 and VEGF-C were associated with longer PFS and ORR. Most treatment-related adverse events were of mild-to-moderate intensity and included fatigue, hypertension, and hand-foot syndrome.
Conclusion: Sunitinib has substantial antitumor activity in patients with bevacizumab-refractory mRCC and modulates circulating VEGF pathway biomarkers. These data support the hypothesis that sunitinib inhibits signaling pathways involved in bevacizumab resistance. Baseline levels of sVEGFR-3 and VEGF-C may have potential utility as biomarkers of clinical efficacy in this setting.
Similar articles
-
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21. Eur J Cancer. 2015. PMID: 25618828 Clinical Trial.
-
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.Cancer. 2010 Dec 1;116(23):5383-90. doi: 10.1002/cncr.25327. Epub 2010 Aug 30. Cancer. 2010. PMID: 20806321 Clinical Trial.
-
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13. Cancer Chemother Pharmacol. 2014. PMID: 24220935 Free PMC article. Clinical Trial.
-
Tolerability of first-line therapy for metastatic renal cell carcinoma.Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Cancer Treat Rev. 2009. PMID: 19249157 Review.
-
Sunitinib malate for the treatment of renal cell carcinoma.Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Expert Opin Pharmacother. 2012. PMID: 22607009 Review.
Cited by
-
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.Int J Mol Sci. 2021 Apr 5;22(7):3765. doi: 10.3390/ijms22073765. Int J Mol Sci. 2021. PMID: 33916438 Free PMC article. Review.
-
Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis.J Pers Med. 2024 May 23;14(6):557. doi: 10.3390/jpm14060557. J Pers Med. 2024. PMID: 38929778 Free PMC article.
-
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Clin Med Insights Oncol. 2016 Apr 27;10(Suppl 1):41-55. doi: 10.4137/CMO.S34542. eCollection 2016. Clin Med Insights Oncol. 2016. PMID: 27147901 Free PMC article. Review.
-
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.Onco Targets Ther. 2012;5:111-7. doi: 10.2147/OTT.S23273. Epub 2012 Jun 18. Onco Targets Ther. 2012. PMID: 22787405 Free PMC article.
-
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.Br J Cancer. 2012 Aug 7;107(4):639-45. doi: 10.1038/bjc.2012.328. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805326 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical